Friday, March 19, 2010
Official Version [PDF] Official Version [HTML] RSS Feed of Notes
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 522 [Docket No. FDA-2010-N-0002] Implantation or Injectable Dosage Form New Animal Drugs; Flunixin
0
AGENCY: Food and Drug Administration, HHS.

Noteshide
No notes yet
 Post a Note
0
ACTION: Final rule.

Noteshide
No notes yet
 Post a Note
0
SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The ANADA provides for the use of flunixin meglumine injectable solution in swine.

Noteshide
No notes yet
 Post a Note
0
DATES: This rule is effective March 19, 2010.

Noteshide
No notes yet
 Post a Note
0
FOR FURTHER INFORMATION CONTACT: John K. Harshman, Center for Veterinary Medicine (HFV-170), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8197, e-mail:john.harshman@fda.hhs.gov.

Noteshide
No notes yet
 Post a Note
SUPPLEMENTARY INFORMATION:
0
Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland, filed ANADA 200-489 that provides for use of FLUNAZINE-S (flunixin meglumine) Injectable Solution in swine for control of pyrexia associated with swine respiratory disease. Cross Vetpharm Group Ltd.'s FLUNAZINE-S is approved as a generic copy of BANAMINE-S, sponsored by Schering-Plough Animal Health Corp. under NADA 101-479. The ANADA is approved as of March 1, 2010, and the regulations are amended in 21 CFR 522.970 to reflect the approval.

Noteshide
No notes yet
 Post a Note
0
In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Noteshide
No notes yet
 Post a Note
0
The agency has determined under 21 CFR 25.33 that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
Noteshide
No notes yet
 Post a Note
0
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Noteshide
No notes yet
 Post a Note
0
List of Subjects in 21 CFR Part 522 Animal drugs.

Noteshide
No notes yet
 Post a Note
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 1. The authority citation for 21 CFR part 522 continues to read as follows:

0
Authority: 21 U.S.C. 360b.

Noteshide
No notes yet
 Post a Note
2. In § 522.970, revise paragraphs (b)(1) and (b)(4) to read as follows:

§ 522.970 Flunixin.

0
(b) * * *
Noteshide
No notes yet
 Post a Note
0
(1) See Nos. 000061, 055529, and 061623 for use as in paragraph (e) of this section.
Noteshide
No notes yet
 Post a Note
0
(4) See No. 059130 for use as in paragraphs (e)(1) and (e)(2) of this section.
Noteshide
No notes yet
 Post a Note
Dated: March 12, 2010. Bernadette Dunham,

Director, Center for Veterinary Medicine.

[FR Doc. 2010-6038 Filed 3-18-10; 8:45 am] BILLING CODE 4160-01-S

Name:
Website (optional):
Note:
   Submit